eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | metabolic syndrome x |
| Symptom | C0242339|dyslipidemia |
| Sentences | 66 |
| PubMedID- 19962289 | Insulin resistance, obesity, hypertension, and dyslipidemia are strongly associated with metabolic syndrome (mesy), which is considered to be a reversible clinical stage before its evolution to coronary heart disease and diabetes. |
| PubMedID- 26504474 | Increased fructose ingestion has been linked to obesity, hyperglycemia, dyslipidemia, and hypertension associated with metabolic syndrome. |
| PubMedID- 25833358 | Obesity, along with hypertension, impaired glucose tolerance or diabetes mellitus and dyslipidemia are well-known factors of metabolic syndrome. |
| PubMedID- 19959757 | They showed that these mice developed insulin resistance, reduced glucose tolerance, and dyslipidemia, all common features of the metabolic syndrome. |
| PubMedID- 25885394 | Although a study reported that patients with nonfunctioning adrenal incidentalomas exhibit higher fasting glucose with insulin resistance and dyslipidemia as part of the metabolic syndrome, this patient had nearly normal blood glucose and diabetic monitoring did not show results of high blood sugar necessitating insulin administration. |
| PubMedID- 20871824 | In vivo and in vitro studies demonstrate that pparα plays a central role in lipid and lipoprotein metabolism, and thereby decreases dyslipidemia associated with metabolic syndrome. |
| PubMedID- 25861160 | To date, oa-no2 is established to have several properties, such as the therapeutic effects against dyslipidemia and hyperglycemia, associated with the metabolic syndrome. |
| PubMedID- 21675801 | Fenofibrate also had a beneficial effect on atherogenic dyslipidemia in patients with the metabolic syndrome or type 2 diabetes mellitus, reducing tg levels, tending to increase hdl-c levels, and promoting a shift to larger low-density lipoprotein particles. |
| PubMedID- 21808028 | Skeletal muscle insulin resistance has been implicated in the pathogenesis of nonalcoholic fatty liver disease (nafld) and atherogenic dyslipidemia associated with the metabolic syndrome by altering the distribution pattern of postprandial energy storage. |
| PubMedID- 26078820 | Nafld, as a hepatic manifestation of metabolic syndrome, is associated with dyslipidemia, obesity, insulin resistance, and type 2 diabetes mellitus . |
| PubMedID- 24205128 | Nafld is a common feature of metabolic syndrome being often associated with obesity, dyslipidemia and diabetes and mostly closely linked to insulin resistance. |
| PubMedID- 20671994 | Obesity in conjunction with type 2 diabetes, hypertension, coronary artery disease (cad), and dyslipidemia are important features of the metabolic syndrome which is usually associated with hyperinsulinemia and insulin resistance . |
| PubMedID- 24511209 | Both proteins are involved in the lipid metabolism and have been suggested to be involved in the dyslipidemia of children with metabolic syndrome . |
| PubMedID- 20718958 | For dyslipidemia associated with metabolic syndrome, recent data have shown that the presence of metabolic syndrome during childhood is associated with the development of coronary disease 25 years later, i.e., in adulthood . |
| PubMedID- 22269613 | Fibrates improve cardiovascular outcomes only in select subgroups: fenofibrate in diabetic patients with metabolic syndrome, gemfibrozil in patients with dyslipidemia, and bezafibrate in patients with diabetes or metabolic syndrome. |
| PubMedID- 21766668 | Principles pharmacotherapy for dyslipidemia associated with metabolic syndrome. |
| PubMedID- 20093718 | dyslipidemia in metabolic syndrome (ms), called the atherogenic triad, includes elevated levels of plasma triglycerides (tgs), low levels of hdl-cholesterol (hdl-ch), and the presence of small dense low-density lipoproteins (sdldls) with normal or slightly elevated ldl-ch levels. |
| PubMedID- 24701430 | Similarly a weaker association was observed between blood pressure and atherogenic dyslipidemia in genetic epidemiology of metabolic syndrome project, a family based study. |
| PubMedID- 24407032 | Dysregulation of intestinal insulin signaling, possibly triggered by oxidative stress and inflammation, was associated with exaggerated lipogenesis and lipoprotein synthesis, which may represent a key mechanism for atherogenic dyslipidemia in patients with metabolic syndrome. |
| PubMedID- 20604930 | It can lead to common mental and somatic disorders such as anxiety, depression, and development of obesity and metabolic syndrome with insulin resistance, dyslipidemia, arterial hypertension, type 2 diabetes, and atherosclerosis ultimately resulting in premature cardiovascular disease and death 1. |
| PubMedID- 25210757 | Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome. |
| PubMedID- 25815329 | In addition, the role of antiretroviral therapy, especially protease inhibitors, has been implicated in the development of metabolic syndrome with insulin resistance, dyslipidemia, and hypertension . |
| PubMedID- 26375703 | Typical feature of dyslipidemia in patients with metabolic syndrome is increase triglycerides, decrease hdl-cholesterol and prezence of small atherogenic ldl particle; nevertheless majority of patients do not reach target level of ldl-cholesterol for their risk category as well. |
| PubMedID- 22448092 | dyslipidemia, one hallmark of the metabolic syndrome. |
| PubMedID- 23757426 | These studies suggest that factors other than hyperglycemia, including metabolic factors such as dyslipidemia or other components of the metabolic syndrome and chronic inflammation, are involved in the pathophysiology of dpn. |
| PubMedID- 22247890 | In vivo and in vitro studies demonstrate that ppar-α plays a central role in lipid and lipoprotein metabolism, and thereby decreases dyslipidemia associated with metabolic syndrome. |
| PubMedID- 22432118 | Insulin resistance promotes endothelial dysfunction, oxidative stress, and inflammation and is closely linked with other cardiovascular risk factors (obesity, hypertension, and dyslipidemia) as part of metabolic syndrome (12). |
| PubMedID- 23032062 | Results: we have identified mir-197, mir-23a, and mir-509-5p as potential contributors of dyslipidemia in metabolic syndrome (correlation with body mass index; p = 0.029, 0.021, and 0.042, respectively) and mir-130a and mir-195 as contributors of hypertension (correlation with blood pressure; p = 0.019 and 0.045, respectively). |
| PubMedID- 23451227 | The results showed that early metabolic syndrome (hyperinsulinemia, dyslipidemia, and hypertension) and prediabetic conditions (impaired fasting glucose) could be induced by high energy diet, and these animals later developed painful polyneuropathy characterized by myelin breakdown and lmf loss in both peripheral and central nervous system. |
| PubMedID- 24529133 | Insulin resistance often occurs with dyslipidemia as part of the metabolic syndrome and the current dominant paradigm is that insulin resistance leads to dyslipidemia. |
| PubMedID- 24478758 | Angptl4 also seems to play a relevant role in type 2 diabetes mellitus and in the metabolic syndrome, both associated with dyslipidemia (52). |
| PubMedID- 20398376 | We have previously shown dex to concomitantly induce both muscle-specific insulin resistance and dyslipidemia in experimental models of metabolic syndrome including spontaneously hypertensive rat-derived congenic strain , polydactylous rat as well as bn 7. |
| PubMedID- 20195400 | This 6-week, multicenter, randomized, open-label, parallel-group, single-dose trial (nct00335699) was designed to compare the efficacy of a single dose of rosuvastatin and atorvastatin in patients having nondiabetic metabolic syndrome with dyslipidemia (fig. |
| PubMedID- 21324458 | Objective: fenofibrate therapy reduces serum triglycerides (tg) and increases high-density lipoprotein-cholesterol (hdl-c) and thus addresses the atherogenic dyslipidemia associated with metabolic syndrome (mets). |
| PubMedID- 26089882 | dyslipidemia as part of the metabolic syndrome is a risk factor for endothelial dysfunction and atherosclerosis as well. |
| PubMedID- 22754464 | In the course of months or years, ir is followed by the increase in β-cell insulin secretion and by several complications known as the insulin resistance syndrome, which is associated with dyslipidemia, hypertension, hyperglycemia and cardiovascular disease 4. |
| PubMedID- PMC4055882 | The cb1 receptor antagonist rimonabant was on the market in europe as an anti-obesity drug, and was considered quite efficacious in lowering weight, reducing waist circumference and ameliorating the dyslipidemia associated with the metabolic syndrome . |
| PubMedID- 23888382 | Furthermore low hdl-c and high tg are ingredients of the dyslipidemia often associated with the metabolic syndrome and type 2 diabetes. |
| PubMedID- 26068528 | Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome. |
| PubMedID- 20507579 | Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a chinese population. |
| PubMedID- 22768054 | Wistar ottawa karlsburg rt1u (wokw) rats are white in color (albino), powerfully built and develop facets of metabolic syndrome with obesity, dyslipidemia, insulin resistance, hyperinsulinemia, hyperleptinemia and glucose intolerance . |
| PubMedID- 24205723 | dyslipidemia in metabolic syndrome and diabetes mellitus features hypertriglycemia and low hdl cholesterolemia. |
| PubMedID- 24454851 | Insulin resistance, as seen in metabolic syndrome, a common cause of dyslipidemia, is thought to be a primary driver of nafld , , . |
| PubMedID- 25875942 | Non-alcoholic fatty liver disease (nafld) is the most common cause of hepatic disease in western civilization . |
| PubMedID- 26579440 | dyslipidemia is strongly associated with metabolic syndrome, obesity, diabetes and fatty liver disease26. |
| PubMedID- 23838610 | Hypertension and dyslipidemia, key components of the metabolic syndrome, also respond to bariatric surgery. |
| PubMedID- 25841249 | Visceral adiposity is part of the metabolic syndrome, together with insulin resistance, dyslipidemia, hypertension and inflammation. |
| PubMedID- 25992080 | In a study published in japan7 involving 275 men, the prevalence of severe osas (ahi > 30) was 1 in 6 individuals with metabolic syndrome (bmi > 30 associated with dyslipidemia and/or hyperglycemia), whereas the prevalence was only 1 in 40 individuals without the metabolic syndrome. |
| PubMedID- 20573750 | Fa + statin in patients with mixed dyslipidemia reduces the prevalence of metabolic syndrome. |
| PubMedID- 24895480 | Atherogenic dyslipidemia prevails in patients with the metabolic syndrome, insulin resistance, and type 2 diabetes in whom it has been established to be a powerful indicator of cvd risk,(22) even being under treatment with ldl-c-lowering drugs such as statins. |
Page: 1 2